Bull Run

Advanced stock screening and portfolio analysis for Indian equity markets.

Navigation

Tools & Features

  • Premium Features
© 2025 Bull Run. All rights reserved.
info@bullrun.co.in

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities. Bull Run is not a SEBI-registered Research Analyst/Investment Adviser.

HomeStocksPharmaceuticalsPfizer Ltd

Pfizer Ltd Stock Price Today (NSE: PFIZER)

Pfizer Ltd

PFIZERPharmaceuticals
₹4954.60+₹0.00 (+0.00%)↑
As on 20 Feb 2026, 06:20 am ISTMarket Closed

Fundamental Score

...

Pfizer Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis

Pfizer Ltd share price today is ₹4954.60, up +0.00% on NSE/BSE as of 20 February 2026. Pfizer Ltd (PFIZER) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹22.74K (Cr). The 52-week high for PFIZER share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 32.18x, PFIZER is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.40% and a debt-to-equity ratio of 0.01.

Pfizer Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
+0.00%

Returns & Performance

Average

ROE

16.40%
Excellent

ROCE

21.62%
Excellent

OPM (5Y)

31.81%

Div Yield

0.70%

Pfizer Ltd Valuation Check

Poor

P/E Ratio

32.18x
Poor

Industry P/E

31.77x
Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Market Cap

22.74K (Cr)

Growth Engine

Good

Profit Growth (Q)

19.37%
Poor

Sales Growth (Q)

9.13%
Poor

Sales Growth (5Y)

1.18%
Poor

EPS Growth (5Y)

4.68%
Poor

Profit Growth (5Y)

4.68%

Balance Sheet Health

Excellent

Debt to Equity

0.01x
Excellent

Int. Coverage

99.16x

Free Cash Flow (5Y)

2.43K (Cr)

Shareholding

Excellent

Promoter

63.92%
Poor

FII

2.60%
Good

DII

17.11%
Excellent

Pledged

0.00%

Institutional Deep-Dive

Bull Run Research Hub

Pfizer Share Price: A Conservative Value Investor's Perspective

The pharmaceutical industry, while often seen as recession-resistant due to consistent healthcare demand, faces unique challenges including intense regulatory scrutiny and patent expirations, impacting long-term profitability. This analysis examines the current valuation of the Pfizer share price (₹4590.2998046875) through the lens of a conservative value investor prioritizing capital safety.

Currently, Pfizer is trading at a Price-to-Earnings (PE) ratio of 32.18. This is a key data point, demanding careful comparison against sector peers. While a higher PE isn't inherently negative, it warrants scrutiny. A thorough investigation, which included looking into historical financial reports of Pfizer, has also been performed. When compared to a company like Mankind Pharma Ltd, a crucial element to consider is the perceived quality of management and their track record in navigating the complex pharmaceutical landscape. Such considerations are essential when gauging future performance and justifying premium valuations.

A significant positive is Pfizer's Return on Capital Employed (ROCE) of 21.62%. A high ROCE indicates efficient capital allocation and potentially a strong competitive moat. In Pfizer's case, this strong ROCE reflects their ability to generate profits from their invested capital, fueled by established brands and research & development capabilities. This efficient use of resources will likely give the company a competitive edge when compared to sector peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, who may have a lower ROCE. A persistently high ROCE strengthens the company's long-term sustainability, a crucial factor for value investors.

This observational analysis is part of a comprehensive 80-parameter fundamental audit conducted and verified by Sweta Mishra. The audit focused on assessing Pfizer's financial health, competitive position, and management effectiveness. The observations above provide a preliminary overview for cautious investors considering the long-term prospects of the company.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Pfizer Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of PFIZER across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (16.40%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (21.62%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (31.81%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (99.16x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹2429.75 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (63.92%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Limited Growth History (1.18% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (4.68% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (4.68% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Pfizer Ltd Financial Statements

Comprehensive financial data for Pfizer Ltd including income statement, balance sheet and cash flow

About PFIZER (Pfizer Ltd)

Pfizer Ltd (PFIZER) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹22.74K (Cr). Pfizer Ltd has delivered a Return on Equity (ROE) of 16.40% and a ROCE of 21.62%. The debt-to-equity ratio stands at 0.01, reflecting the company's capital structure. Investors tracking PFIZER share price can monitor key metrics including P/E ratio, promoter holding of 63.92%, and quarterly earnings growth.

Company Details

Symbol:PFIZER
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:https://www.pfizerltd.co.in

Key Leadership

Ms. Meenakshi Nevatia
MD, CEO & Director
Mr. Prajeet Nair C.S.
Director of Corporate Services, Company Secretary & Compliance Officer
Mr. Pazhania Pillai Rengan
Whole-Time Director & Executive Director of Plant Operations

Corporate Events

Upcoming
Earnings Date
2026-01-29
Recent
Ex-Dividend Date
2025-07-09

Latest News

Trending tickers: Snap, Pfizer, Tata Consultancy Services, Samsung Electronics and Oklo - Yahoo Finance UK
Yahoo Finance UK• 9/22/2025
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Yahoo Finance• 10/9/2025
Nifty outlook indecisive, says Vinay Rajani; picks 2 stocks to buy today - Business Standard
Business Standard• 1/8/2025

PFIZER Share Price: Frequently Asked Questions

What is the current share price of Pfizer Ltd (PFIZER)?

As of 20 Feb 2026, 06:20 am IST, Pfizer Ltd share price is ₹4954.60. The PFIZER stock has a market capitalisation of ₹22.74K (Cr) on NSE/BSE.

Is PFIZER share price Overvalued or Undervalued?

PFIZER share price is currently trading at a P/E ratio of 32.18x, compared to the industry average of 31.77x. Based on this relative valuation, the Pfizer Ltd stock appears to be Overvalued against its sector peers.

What is the 52-week high and low of PFIZER share price?

The 52-week high of PFIZER share price is ₹N/A and the 52-week low is ₹N/A.

What factors affect the Pfizer Ltd share price?

Key factors influencing PFIZER share price include quarterly earnings growth (Sales Growth: 9.13%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Pfizer Ltd a good stock for long-term investment?

Pfizer Ltd shows a 5-year Profit Growth of 4.68% and an ROE of 16.40%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in PFIZER shares.

How does Pfizer Ltd compare with its industry peers?

Pfizer Ltd competes with major peers in the Pharmaceuticals. Investors should compare PFIZER share price P/E of 32.18x and ROE of 16.40% against the industry averages to determine competitive standing.

What is the P/E ratio of PFIZER and what does it mean?

PFIZER share price has a P/E ratio of 32.18x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.

How is PFIZER performing according to Bull Run's analysis?

PFIZER has a Bull Run fundamental score of 55/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does PFIZER belong to?

PFIZER operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Pfizer Ltd share price.

What is Return on Equity (ROE) and why is it important for PFIZER?

PFIZER has an ROE of 16.40%, which indicates excellent management efficiency. ROE measures how efficiently Pfizer Ltd generates profits from shareholders capital.

How is PFIZER debt-to-equity ratio and what does it indicate?

PFIZER has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.

What is PFIZER dividend yield and is it a good dividend stock?

PFIZER offers a dividend yield of 0.70%, meaning you receive ₹0.70 annual dividend for every ₹100 invested in Pfizer Ltd shares.

How has PFIZER share price grown over the past 5 years?

PFIZER has achieved 5-year growth rates of: Sales Growth 1.18%, Profit Growth 4.68%, and EPS Growth 4.68%.

What is the promoter holding in PFIZER and why does it matter?

Promoters hold 63.92% of PFIZER shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Pfizer Ltd.

What is PFIZER market capitalisation category?

PFIZER has a market capitalisation of ₹22739 crores, placing it in the Large-cap category.

How volatile is PFIZER stock?

PFIZER has a beta of N/A. A beta > 1 suggests the Pfizer Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is PFIZER operating profit margin trend?

PFIZER has a 5-year average Operating Profit Margin (OPM) of 31.81%, indicating the company's operational efficiency.

How is PFIZER quarterly performance?

Recent quarterly performance shows Pfizer Ltd YoY Sales Growth of 9.13% and YoY Profit Growth of 19.37%.

What is the institutional holding pattern in PFIZER?

PFIZER has FII holding of 2.60% and DII holding of 17.11%. Significant institutional holding often suggests professional confidence in the Pfizer Ltd stock.

HomeScreenerBattleWatchlist